Regulation of attention and response to therapy in dementia by butyrylcholinesterase

Pharmacogenetics

Volumn 13, Issue 4, 2003, Pages 231-239

  O'Brien, Kirsty K ^a,b   Saxby, Brian K ^c   Ballard, Clive G ^c   Grace, Jan ^c   Harrington, Frances ^c   Ford, Gary A ^c,e   O'Brien, John T ^c   Swan, Alan G ^c   Fairbairn, Andrew F ^c   Wesnes, Keith ^d   Del Ser, Teodoro ^f   Edwardson, James A ^a,e   Morris, Christopher M ^a,b,e   McKeith, Ian G ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Centre for Life   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d University of Newcastle ^*  (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

Acetylcholine; Alzheimer's disease; Butyrylcholinesterase; Cognition; Dementia; Lewy body

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR;

AGED; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MEMORY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ATTENTION; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; COGNITION; DEMENTIA; DNA; DNA PRIMERS; GENOTYPE; HUMANS; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION;

EID: 0038408676     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200304000-00008     Document Type: Article

References (31)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2:1403.
2. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30:113-121.
3. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-414.
4. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5:747-749.
5. Levy JA, Parasuraman R, Greenwood PM, Dukoff R, Sunderland T. Acetylcholine affects the spatial scale of attention: evidence from Alzheimer's disease. Neuropsychology 2000; 14:288-298.
6. Wesnes K, Simpson PM, Kidd AG. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg. Hum Psychopharmacol 1998; 3:27-43.
7. Singleton AB, Gibson AM, Edwardson JA, McKeith IG, Morris CM. Butyrylcholinesterase K: an association with dementia with Lewy bodies. Lancet 1998; 351:1818.
8. Schwarz M, Glick D, Loewenstein Y, Soreq H. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol Ther 1995; 67:283-322.
9. Forbat A, Lehmann H, Silk E. Prolonged apnea following injection of succinylcholine. Lancet 1953; 2:1067-1068.
10. Bartels CF, James K, La Du BN. DNA mutations associated with the human butyrylcholinesterase J-variant. Am J Hum Genet 1992; 50:1104-1114.
11. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA 1989; 86:953-957.
12. Lehmann DJ, Johnston C, Smith Alzheimer's disease. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997; 6:1933-1936.
13. Chapman J, Estupinan J, Asherov, A. Goldfarb LG. A simple and efficient method for apolipoprotein E genotype determination. Neurology 1996; 46:1484-1485.
14. Simpson P, Surmon D, Wesnes K, Wilcock G. The Cognitive Drug Research Computerized Assessment System for Demented Patients: A validation study. Int J Geriat Psych 1991; 6:95-102.
15. Nichol C. Lynch S, Kelly C, White L, Simpson P, Wesnes K, et al. The Cognitive Drug Research Assessment System in the evaluation of early dementia-is speed of the essence? Int J Geriat Psych 1995; 10:199-206.
16. Mohr E, Walker D, Randolph C, Sampson M, Mendis T. Utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. Int Psychogeriat 1996; 8:397-411.
17. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036.
18. Harrington F, Saxby BK, McKeith IG, Wesnes K, Ford GA. Cognitive performance in hypertensive and normotensive older subjects. Hypertension 2000; 36:1079-1082.
19. Launer LJ, Masaki K, Petrovich H, Foley D, Havlik RJ. The association between blood pressure levels and late life cognitive function: The Honolulu-Asia Aging Study. JAMA 1995; 274:1846-1851.
20. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: A 20-year follow up of 999 men. Hypertension 1998; 31:80-786.
21. Folstein M, Folstein S, McHugh P. 'Mini-Mental State' A practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975; 12:189-198.
22. Morris J. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993; 43:2412-2418.
23. Jorm A, Scott R, Cullen J, McKinnon A. Performance of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening test for dementia. Psychol Med 1991; 21:785-790.
24. Nelson H, O'Connell A. Dementia: The estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex 1978; 14: 234-244.
25. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psych Res 1982; 17:37-49.
26. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51:145-155.
27. McIlroy SP, Crawford VL, Dynan KB, McGleenon BM, Vahidassr MD, Lawson JT, et al. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Genet 2000; 37:182-185.
28. Wiebuseh H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999; 104:158-163.
29. Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG, et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet 1998; 7:937-939.
30. Brindle N, Song Y, Rogaeva E, Premkumar S, Levesque G, Yu G, et al. Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. Hum Mol Genet 1998; 7:933-935.
31. Kehoe PG, Williams H, Holmans P, Wilcock G, Cairns NJ, Neal J, et al. The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease. J Med Genet 1998; 35:1034-1035.